The Quantellect read.As of Nov 19, 2026, 3 active firms cover Inovio Pharmaceuticals Inc: 2 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $2.50 to $4.00, a moderate spread. The average target of $3.17 sits 88% above the current $1.68. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.17 next quarter toward $-0.35 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy267%
Neutral133%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$3.17
+88.5% upside
Average target across 3 active firms as of Nov 19, 2026 vs $1.68 current
Highest Target$4.00
Average Target$3.17
Lowest Target$2.50
Detailed analyst forecasts for INO
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 2 of 3 active firms rate INO a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
INO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.17
Range $-0.22 – $-0.12 · 2 analysts · -45% YoY
Next period, 2 analysts expect Inovio Pharmaceuticals Inc to earn $-0.17 a share (range $-0.22 – $-0.12), versus $-0.31 a year earlier. Full-year consensus is $-0.90, growing to $-0.35 the year after.
REVENUE · NEXT QUARTER
$7.0M
Range $6.0M – $8.0M · 2 analysts
Revenue is expected to reach $7.0M (range $6.0M – $8.0M). Full-year consensus is $349.3K, rising to $43.3M next year.
Top analysts covering Inovio Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on INO.
#1
Roger Song
Jefferies · Rank #122
Buy
$3.00+78.6% to target
Overall win rate
43%
+ Follow
#2
Roy Buchanan
JMP Securities · Rank #176
Buy
$12.00+614.3% to target
Overall win rate
47%
+ Follow
#3
Gregory Renza
RBC Capital · Rank #277
Neutral
$5.00+197.6% to target
Overall win rate
35%
+ Follow
#4
Raghuram Selvaraju
HC Wainwright & Co. · Rank #423
Neutral
$2.50+48.8% to target
Overall win rate
36%
+ Follow
#5
Edward Tenthoff
Piper Sandler · Rank #460
Buy
$4.00+138.1% to target
Overall win rate
29%
+ Follow
INO stock forecast FAQ
What is INO's average 12-month price target?+
The 3 active firms with a live target average $3.17 for Inovio Pharmaceuticals Inc over the next 12 months, ranging from a $4.00 high to a $2.50 low, as of Nov 19, 2026.
Is INO stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for INO?+
The Street-high target is $4.00 (Piper Sandler), and the Street-low is $2.50 (HC Wainwright & Co.). The average of all 3 active-firm targets is $3.17.
How many active Wall Street firms cover INO?+
3 active firms have a recognized rating on Inovio Pharmaceuticals Inc as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering INO?+
Among analysts who currently cover INO, Roger Song of Jefferies has the strongest overall Quantellect track record (Rank #122). Their current call is Buy with a $3.00 target.
What is Inovio Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.17 per share (range $-0.22 – $-0.12) across 2 analysts. Full-year EPS is projected at $-0.90, rising to $-0.35 the following year.
How much revenue is Inovio Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $7.0M (range $6.0M – $8.0M). Full-year revenue is projected at $349.3K, growing to $43.3M next year.
Have analysts been upgrading or downgrading INO lately?+
As of Nov 19, 2026, 2 of 3 active firms rate INO a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their INO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.